Skip to main content
OpenTrials
Completed

NCT Number: NCT07671755

Colistin Versus Colistin Combined With Cefoperazone-sulbactam for Multiresistant Acinetobactor Baumannii Ventilator-associated Pneumonia Treatment

This study aims to evaluate clinical outcomes of colistin versus colistin in combination with cefoperazone-sulbactam for patients with MDR-AB VAP treatment.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Clinical Response Cross Infection Disease Attributes Healthcare-Associated Pneumonia Iatrogenic Disease Infections Lung Diseases Pathologic Processes Pathological Conditions, Signs and Symptoms Pneumonia Pneumonia, Ventilator-Associated Radiological Response Respiratory Tract Diseases Respiratory Tract Infections

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Shaheed Mohtarma Benazir Bhutto Institue of Trauma

Karachi, Pakistan

About this study

MDR-AB (multidrug-resistant Acinetobacter baumannii) has been an increasingly common cause of ventilator-associated pneumonia (VAP) in intensive care unit (ICU). Colistin remains the last available antibiotic choice. Unfortunately, colistin monotherapy is often inadequate for microbiologic eradication and a risk factor of nephrotoxicity and for heteroresistance.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients with a diagnosis of VAP due to A. baumannii

Exclusion criteria

  • patients who had polymicrobial VAP
  • Patients with pre-existing severe renal failure and/or abnormal liver function tests
  • Patients allergic to colistin or cefoperazone-sulbactam

Treatment and study plan

colistin plus cefoperazone-sulbactam combination group

Drug

Combination therapy

Colistin

Drug

Monotherapy

Primary outcomes

  1. Clinical response

    Time frame: within one week

    Clinical response was defined as observable improvement in the patient's clinical signs/symptoms, including absence of fever (temp<38ºC) for three consecutive days or more, and decreasing amount and purulence of tracheal secretions

Secondary outcomes

  1. Radiological response

    Time frame: within one week

    Radiological response was defined as improvement/resolution of pulmonary infiltrates, as noted on chest x-rays following treatment.

Sponsors and collaborators

Lead sponsor

Shaheed Mohtarma Benazir Bhutto Institue of Trauma

Other

Registry information

Acronym: CRAB

Important dates

Study start
2025
Primary completion
2025
Study completion
2026
First posted
Jun 26, 2026
Registry last updated
Jun 26, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.